(MedPage Today) — SAN FRANCISCO — Givinostat (Duvyzat) had a manageable long-term safety profile in Duchenne muscular dystrophy, data from an open-label extension study suggested.
Most treatment-emergent adverse events (TEAEs) were mild to…
Source link : https://www.medpagetoday.com/meetingcoverage/aanem/118270
Author :
Publish date : 2025-11-01 22:00:00
Copyright for syndicated content belongs to the linked Source.
